- Trials with a EudraCT protocol (28)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
28 result(s) found for: Pi Pi Interaction.
Displaying page 1 of 2.
EudraCT Number: 2021-002565-17 | Sponsor Protocol Number: WODDOL | Start Date*: 2021-12-02 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: Multi-center study to evaluate virological efficacy, safety tolerability, drug exposure and patients’ reported outcomes over 48 weeks following randomization to 2-drug therapy with DTG/3TC FDC or c... | |||||||||||||
Medical condition: HIV-1-infected adult women of >18 years of age, without previous virologic failure, currently receiving an effective (HIV-RNA < 50 copies/ml) triple-drug cART, containing tenofovir (TAF or TDF) in ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001866-15 | Sponsor Protocol Number: 1182.71 | Start Date*: 2007-07-12 |
Sponsor Name:Boehringer Ingelheim France SAS | ||
Full Title: A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista® (Darunavir, DRV/r) in three-clas... | ||
Medical condition: HIV infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) ES (Completed) DE (Prematurely Ended) GR (Completed) PT (Prematurely Ended) IT (Prematurely Ended) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004698-39 | Sponsor Protocol Number: 1188.31 | Start Date*: 2006-02-03 |
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | ||
Full Title: Randomized, double-blind, placebo-controlled 7 day monotherapy Phase IIa study to evaluate the antiviral activity and safety of oral administered RTV-boosted BILR 355 (75 mg and 150 mg twice daily... | ||
Medical condition: This randomized, placebo-controlled, double-blind trial will be conducted in HIV-1 infected patients who have experienced virological failure with at least one NNRTI-based HAART regimen. The treatm... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-011172-30 | Sponsor Protocol Number: A9951007 | Start Date*: 2009-08-10 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 2 DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS/ PHARMACODYNAMICS OF PF-04360365 IN MILD TO MODERATE ALZHEIMER’S... | |||||||||||||
Medical condition: Mild to Moderate Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003163-31 | Sponsor Protocol Number: AI424-328 | Start Date*: 2006-11-28 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine with or without Tenofovir on the Pharmacokinetics of Atazanavir when given with Ritonavir in HIV-Infected Subjec... | |||||||||||||
Medical condition: HIV infected Subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002501-22 | Sponsor Protocol Number: PHP-303-A201 | Start Date*: 2020-05-04 |
Sponsor Name:pH Pharma Inc. | ||
Full Title: A Multi-Center, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Tolerability of the Neutrophil Elastase Inhibitor PHP-303 in Adults with Alpha-1 Antitrypsin Defic... | ||
Medical condition: Alpha-1 Antitrypsin Deficiency | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000121-32 | Sponsor Protocol Number: 68284528MMY2001 | Start Date*: 2019-09-03 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma | |||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000777-24 | Sponsor Protocol Number: TAK-994-1501 | Start Date*: 2021-05-17 |
Sponsor Name:Takeda Development Center Americas, Inc. | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy W... | ||
Medical condition: Narcolepsy With or Without Cataplexy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) FR (Prematurely Ended) CZ (Completed) NL (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-000986-42 | Sponsor Protocol Number: A9951002 | Start Date*: 2008-10-21 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE DOSES OF PF-04360365 IN PATIENTS WITH MILD TO MODERATE ALZHEI... | |||||||||||||
Medical condition: MILD TO MODERATE ALZHEIMER’S DISEASE | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003200-23 | Sponsor Protocol Number: 2013DR3084 | Start Date*: 2016-04-21 |
Sponsor Name:University Hospital Basel; Neurology | ||
Full Title: Biomarkers and antithrombotic treatment in cervical artery dissection (TREAT-CAD) | ||
Medical condition: cervical artery dissection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004079-38 | Sponsor Protocol Number: 01112012 | Start Date*: 2013-01-14 |
Sponsor Name:Central Institute of Mental Health, Department of Psychiatry and Psychotherapy | ||
Full Title: Agomelatine treatment of major depressive episodes in the course of schizophrenic psychoses (AGOPSYCH). A single arm, prospective pilot study | ||
Medical condition: Major depressive episode | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-003866-13 | Sponsor Protocol Number: CCR102881 | Start Date*: 2005-02-24 |
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||
Full Title: A phase IIb, 96 week, randomised, partially,double-blinded,multicentre,parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW873140 in c... | ||
Medical condition: Treatment of HIV-1 infections | ||
Disease: | ||
Population Age: Adolescents, Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) IT (Prematurely Ended) GB (Prematurely Ended) BE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001839-77 | Sponsor Protocol Number: 5mille_CT1 | Start Date*: 2022-04-26 | |||||||||||
Sponsor Name:IRCCS MATERNO INFANTILE BURLO GAROFOLO | |||||||||||||
Full Title: A Multicentric, Drug-Repositioning, Self Controlled Case Series (SCCS) Clinical Trial to Evaluate the Efficacy and Safety of Perampanel in Improving Behavioral Symptoms and Increasing the Quality o... | |||||||||||||
Medical condition: Patients with POGZ related disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002302-43 | Sponsor Protocol Number: CHDR1209 | Start Date*: 2012-06-08 | ||||||||||||||||
Sponsor Name:Dr. Reddy's Laboratories Ltd. | ||||||||||||||||||
Full Title: A study to investigate the analgesic effects of buprenorphine and milnacipram in healthy volunteers. | ||||||||||||||||||
Medical condition: Pain therapeutics, neuropathic pain, nociceptive pain, synergism between opioids and TCA. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000347-41 | Sponsor Protocol Number: N17DEX | Start Date*: 2017-04-19 | |||||||||||
Sponsor Name:Modra Pharmaceuticals BV | |||||||||||||
Full Title: Safety of extended use of the weekly oral docetaxel formulation ModraDoc006/r in patients with advanced solid tumours | |||||||||||||
Medical condition: Advanced solid malignancies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002400-26 | Sponsor Protocol Number: 64407564MMY1001 | Start Date*: 2019-02-06 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | |||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) FR (Ongoing) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003459-12 | Sponsor Protocol Number: CE1226_4001 | Start Date*: 2006-01-30 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase III/IV Study to compare the Efficacy and Safety of 60 mg/kg body weight of Zemaira® weekly i.v. administration with Placebo weekly ... | |||||||||||||
Medical condition: Chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) DE (Completed) FI (Completed) EE (Completed) SE (Completed) CZ (Completed) DK (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000974-22 | Sponsor Protocol Number: MRX-701 | Start Date*: 2021-01-29 | |||||||||||
Sponsor Name:Mirum Pharmaceuticals Inc. | |||||||||||||
Full Title: Randomized, Double-blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects with Biliary Atresia after Hepatoportoenterostomy | |||||||||||||
Medical condition: Biliary atresia (BA) is a rare, inflammatory condition of the biliary tree that presents in the first weeks of life and leads to bile duct obstruction and consequent liver injury, fibrosis and cirr... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Ongoing) PL (Completed) GB (GB - no longer in EU/EEA) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006953-41 | Sponsor Protocol Number: C08-002B | Start Date*: 2009-08-19 | |||||||||||
Sponsor Name:ALEXION PHARMACEUTICALS, INC. | |||||||||||||
Full Title: AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS) | |||||||||||||
Medical condition: Adolescent patients (from 12 and up to 18 years of age weighing ≥ 40 kg) with plasma therapyresistant Atypical Hemolytic-Uremic Syndrome (aHUS). | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) SE (Completed) AT (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010887-41 | Sponsor Protocol Number: TMC125-TiDP2-C238 | Start Date*: 2009-06-22 | |||||||||||
Sponsor Name:Tibotec Pharmaceuticals | |||||||||||||
Full Title: A randomized, exploratory, open-label 48-week trial with a 2-week Pre-Treatment Phase to investigate the pharmacokinetics, safety, tolerability and antiviral activity of etravirine (ETR) in combina... | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.